Recent Finacing
Recent Raise
Helicore Biopharma develops GIP-antagonist therapeutics, including clinical-stage monoclonal antibody HCR-188, antibody conjugates and GLP-1 combinations, leveraging human genetics, preclinical data, Ridgeline and Versant-supported R&D.
